Belantamab Mafodotin Results Reported for Myeloma
Clinical data showcased a BCMA-directed treatment for patients with relapsed or refractory multiple myeloma.
Updated on Oct. 7, 2026 in Cancer
Dr. Paul Richardson presented clinical findings from the DREAMM-7 study on belantamab mafodotin for multiple myeloma. The study evaluated progression-free and overall survival outcomes for the antibody-drug conjugate.
Why it matters
The treatment provides a critical alternative for patients who cannot receive CAR T-cell therapy or bispecific antibodies. As an off-the-shelf option, it expands accessibility for those requiring specialized care.
The DREAMM-7 study measured the performance of this BCMA-directed antibody-drug conjugate. Researchers are still investigating the full scope of treatment durability beyond the initial clinical trial timeframe.
The players
Dr. Paul Richardson
He is a medical expert who presented the clinical data regarding the use of belantamab mafodotin for multiple myeloma patients.
The details
The therapy is administered on an outpatient basis, with ocular monitoring and dosing adjustments used to mitigate potential ocular toxicity. It functions as an off-the-shelf clinical option for treating relapsed or refractory multiple myeloma.
Timeline
October 7, 2026: The article reporting these clinical findings was published.
The Big Picture
This report on the DREAMM-7 study helps define the clinical role of BCMA-directed conjugates in the current standard of care. It follows a pattern set by previous research into optimizing survival outcomes for relapsed myeloma patients.
Patients may now access this therapy in an outpatient setting, potentially reducing the need for lengthy inpatient stays. Clinicians will continue to prioritize ocular monitoring to manage the specific side effects associated with this medication.
The takeaway
This treatment offers a flexible, off-the-shelf option for those ineligible for more complex immunotherapy approaches. Ongoing clinical monitoring remains essential for patients to manage potential ocular side effects during the course of their care.
Further reading
For more on treatment advancements, explore the Cancer section.
Source note: This article includes information reported by OncLive.
